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CHRONIC TRAUMATIC ENCEPHALOPATHY 
AND THE LOCUS COERULEUS 
RYAN J. HEALY 
ABSTRACT 
 Chronic Traumatic Encephalopathy (CTE) is a neurodegenerative disease that is 
associated with repetitive traumatic brain injury like those sustained in sport, military 
combat, and other activities with repetitive head impact exposure. Repetitive head 
impacts typically cause mild traumatic brain injury (mTBI) resulting in both concussive 
and subconcussive injury. Repeated mTBIs injuries appear to cause an abnormal 
accumulation of proteins, including hyperphosphorylated tau (p-tau) and TDP-43, 
progressive axonal failure with gradual structural degradation, microvascular disruption, 
breach of blood-brain barrier, neuroinflammation and microglial activation; each of these 
manifestations lead to axonal degeneration and neuronal death, which impairs neuronal 
pathways and are likely to give rise to CTE symptoms. CTE can be microscopically 
characterized mainly by p-tau accumulation in perivascular spaces and at the depths of 
the cortical sulci. Clinical presentation of CTE may include behavioral, mood, cognitive, 
or motor symptoms. Some of the common symptoms include impulsivity, aggression, 
anxiety, depression, memory impairment, dementia, and suicidality. The Locus Coeruleus 
(LC), a nucleus in the pons of the brainstem, is suspected to be involved in CTE. The LC 
provides the main source of norepinephrine to the entire brain and is critical for its 
control over arousal, behaviors, attention, and memory. Dysfunction of the locus 
coeruleus has shown to cause a wide array of symptoms, many of which are similar to 
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those seen in CTE. Furthermore, the LC is affected in many other neurodegenerative 
diseases and is believed to be responsible for the progressive and widespread nature of 
the various diseases and their clinical symptoms. Although the LC has been implicated in 
CTE there have been no studies examining LC pathology in relation to the disease 
progression or its symptoms. We hypothesize LC CTE pathology should increase with 
the severity of CTE. Furthermore, increased CTE pathology in the LC should create 
disturbances to the LC and the LC-NE system and manifest clinically. Specifically, LC 
CTE pathology may be associated with age of onset of general behavioral and cognitive 
symptoms as well as individual symptoms and outcomes including impulsivity, 
depression, depressed mood and death by suicide. To determine this, a postmortem study 
was performed on 184 individuals with a history of RHI and no comorbid diseases 
examining the relationship between AT8-immunopositive tau density in the LC and 
various clinical variables. The study found that LC AT8 density showed a significant 
positive correlation with duration of repetitive head impact (RHI) exposure when 
controlled for age. There also was a significant increase in LC AT8-immunoreactive tau 
in cases with stage III and IV CTE compared to those with no CTE and stage I and II 
CTE, and AT8 density was predictive of CTE stage when controlled for age. There were 
no significant relationships found between density of LC AT8-immunoreactive tau and 
age of any CTE symptom onset or individual symptom (impulsivity, depressed mood, 
MDD, death by suicide) presence. Future studies should continue to evaluate CTE 
pathology in the LC and its effects on both the pathological and clinical characteristics of 
the disease. 
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INTRODUCTION 
 
History of CTE 
Chronic Traumatic Encephalopathy (CTE) is a progressive neurodegenerative 
disease that is associated with repetitive traumatic brain injury like those sustained in 
sport, military combat, and other activities with head impact exposure. In recent years, 
CTE has gained media attention due to the growing evidence that associates the disease 
with American football and its prevalence among former National Football League 
(NFL) players. Although there has been a recent explosion of media interest in CTE, the 
disease was first discussed in the medical literature decades ago in association with the 
sport of boxing. 
The first medical study that began paving the way for future CTE research was 
done by two neurologists Osnato and Giliberti in 1927. These investigators studied 100 
cases of concussion and pathologically examined one case of acute traumatic brain injury 
(TBI). From their microscopic examinations of this brain tissue they concluded that 
following initial brain injury there may be subsequent chronic injury such that complete 
resolution may not occur and can potentially lead to the development of secondary 
degenerative changes. Their microscopic findings resembled encephalitis, permitting 
their diagnosis of ‘traumatic encephalitis’, later renaming this pathology traumatic 
encephalopathy 1,2.  
A year later in 1928 the clinical syndrome that followed traumatic injury was first 
described by Dr. Harrison Martland, a New Jersey pathologist and medical examiner. 
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Although the symptoms were widely known by boxers and the general public, he 
introduced the term “punch drunk” into medical literature, whereby he describes the 
symptoms and neurological deterioration of impaired boxers who he examined. The 
symptoms were described as affecting muscular movements, mental attitude, speech and, 
in severe cases, caused parkinsonian syndrome and marked mental deterioration that 
required the patient be committed to an asylum 3. Martland postulated that 50% of 
fighters develop this condition in mild or severe form if they kept at the sport long 
enough or if they were able to sustain a large number of blows to the head, suggesting 
that the volume of hits was critical to its development. Furthermore, Martland even 
attributed milder forms of concussions to neuronal damage without the occurrence of 
actual hemorrhages and noted that some hemorrhages manifest into gliosis or progressive 
degenerative lesions in specific areas of the brain. These lesions, he proposed, were likely 
responsible for the physical manifestations of “punch drunk” syndrome 4.  
Following this work, in 1937 Millspaugh introduced the term “dementia 
pugilistica” to replace the term “punch drunk” to give the term a less derisive connotation 
and “medicalize” the condition4. The term was meant to convey a physical-psychological 
syndrome that accumulated from a lengthy boxing career. Millspaugh described more 
examples of both the cognitive and physical dysfunctions of boxers, including dementia, 
disorientation, delusion, shuffling gait, and transient paralysis, and was even able to note 
that this mental unbalance can also be seen in players of other sports with frequent head 
trauma 4,5. Additionally, Millspaugh pointed out that repeated and frequent concussions 
disrupt the normal mental state, further building upon the repetitive nature of the disease4. 
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The term chronic traumatic encephalopathy was first coined by Bowman and Blau 
in 1940 after examining the history and symptoms of a 28-year-old professional boxer 6. 
This boxer was described as having paranoia, violent outbursts, poor orientation, unable 
to grasp simple concepts, and had poor short-term memory. The authors of this study 
initially diagnosed the boxer with traumatic encephalopathy; however, after seeing that 
his condition did not improve in the long-term, they re-classified the condition as chronic 
traumatic encephalopathy 2.  
Macdonald Cirtchley, a British neurologist, later published more groundbreaking 
studies on chronic traumatic encephalopathy. His study in 1949 examined 21 subjects 
noting that the condition was not observable until years after beginning boxing, 
specifically noting an average delayed onset of 16 years. In Critchley’s 1957 study, he 
examined 69 boxers and concluded that the condition was seen more in men who were 
able to endure many more hits and beatings than others, which was consistent with claims 
made in previous years.7 This is important in that he was able to take notice that the 
volume of hits and duration of play was an important factor in this condition. He further 
described chronic traumatic encephalopathy as a condition that caused personality 
changes, emotional lability, progressively slower speech and thought, memory 
deterioration, headaches, and lack of awareness 4,7. Furthermore, Cirtchley was able to 
see that once the boxer had been subject to impacts sufficient to establish the disorder, the 
condition was irreversible and progressed steadily despite stopping the sport of boxing 7. 
Eventually in 1973, Corsellis and colleagues published the first robust 
neuropathological study, which looked at patient histories and brain autopsies of 15 
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different retired boxers 5,8. The authors consistently noted neurological changes that were 
atypical for men of their age. Upon both gross and microscopic examination of the brains, 
they were able to note a characteristic pattern of injury (distinct from other 
neurodegenerative conditions like Alzheimer’s and Parkinson’s), cerebral atrophy, and 
histopathological changes in the brain secondary to protein deposition4,5. Moreover, the 
authors interviewed family members of the deceased boxers. Each boxer was described 
by their respective families as presenting with the same characteristic symptoms as 
described in the previous studies on punch-drunk syndrome, dementia pugilistica, or 
chronic traumatic encephalopathy. The authors concluded that the neuropathological 
changes they discovered were most likely the cause of the symptoms seen in chronic 
traumatic encephalopathy, paving the way for future neuropathological studies of the 
disease. 
Although CTE was only recently diagnosed in football players, it is important to 
note it was known for decades that football exposure caused neurological issues similar 
to those of boxing. Actually, many of the authors who first wrote about the disease in 
boxers also noted similar issues in American football players. Osnato and Giliberti wrote 
that traumatic encephalopathy might occur in football and other sports players who get 
knocked out. Martland wrote in a paper that punch drunk was “not uncommon” in 
football players 2. Bowman & Blau postulated that the mental deterioration of the 
condition was due to “repeated head injuries occurring in certain types of professional 
pugilists and football players” 6. Furthermore, case reports about punch drunk in football 
players began appearing in medical journals in the 1930s and has continued throughout 
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time. Reports discuss abnormal behavioral, cognitive, and emotional disturbances that 
football players display, all of which were similar to the symptoms of punch-drunk 
boxers 2.  
However, in 2002 Bennet Omalu reported the first case of neuropathologically 
confirmed CTE in a retired NFL player, Mike Webster, who was a NFL Hall of Fame 
center 9. Webster died of a heart attack at the age of 50, but leading up to his death he had 
a strong history of cognitive and neuropsychiatric problems. Over the years following his 
retirement from football, Webster developed significant memory impairment, mood 
disorder, judgement deficit, parkinsonian symptoms and was reported to be fully 
demented prior to his death 2,9. Upon microscopic examination of Webster’s brain, Omalu 
found an accumulation of hyperphosphorylated tau (p-tau), and concluded that Webster’s 
brain met the criteria for no other diseases but CTE. Not only did Omalu report the 
findings of the histological changes caused by CTE, but he also attributed this case to 
repetitive head injury sustained during football play 9. Although his case report did not 
confirm the causal link between football and CTE, it sparked further research into the 
disease and began to make the general public aware of the severe, long term risks of 
football. Since this initial discovery, there has been hundreds of more individuals 
(athletes and non-athletes) who have been diagnosed with CTE and have a history of 
repetitive head impacts. 
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Epidemiology of CTE 
Sports participation and physical exercise is critically important to physical and 
psychological health, disease resilience, among countless other benefits. However, 
considering recent evidence regarding repetitive head impacts in relation to CTE, contact 
sports pose a potential long-term danger. The incidence and prevalence of CTE is 
unknown, but the number that may potentially be affected is quite large. Mild traumatic 
brain injury is extremely common, affecting about 42 million people annually world-wide 
10. Based on data from the Centers for Disease Control and Prevention, at least 1.6 to 3.8 
million sports-related TBIs occur each year, with many more likely going undiagnosed 
11,12. Many sports have been associated with CTE, including boxing, American football, 
ice hockey, soccer, rugby, and wrestling. CTE has also been identified in military 
veterans, individuals who participate in self-injurious head-banging behavior, victims of 
physical abuse, poorly controlled epileptics, among others with repetitive head injury 13. 
Among athletes that have high exposure to repetitive head impacts, like football players, 
CTE has been neuropathologically confirmed in 50% to 97% of players that have 
undergone study— although it is important to keep in mind the recruitment bias of brain 
banks10. 
American football remains the sport most commonly associated with CTE. In 
2012 it was estimated that there are about 4.2 million total football participants in the 
United States 14. Furthermore, a retrospective analysis of 3,439 NFL players with at least 
5 years of play from 1959 to 1988 showed this population had three times as many deaths 
from neurodegenerative diseases compared to the general population and that CTE may 
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be a primary or secondary cause of many of these deaths 15. In a study of 202 deceased 
players of American football, CTE was neuropathologically diagnosed in 177 players 
across all levels of play, including 110 of 111 former NFL players 16. With a high 
proportion of players showing pathological evidence of CTE, this may suggest that CTE 
is related to prior participation in football and further supports the underlying theory that 
repetitive head impacts are a major risk factor for the disease.  
Due to the high prevalence of repetitive head impacts throughout many sports, behaviors, 
and activities, CTE poses an enormous potential public health risk and, therefore, 
demands further research. 
 
Pathogenesis/Pathophysiology of CTE 
CTE is a neurodegenerative disease that is associated with a history of repetitive 
head impacts, like those sustained through contact sports or military combat. Repetitive 
head impacts typically cause mild traumatic brain injury (mTBI) resulting in both 
concussive and subconcussive injury. Repeated mTBIs injuries cause an abnormal 
accumulation of proteins, including p-tau and TDP-43, progressive axonal failure with 
gradual structural degradation, microvascular disruption, breach of blood-brain barrier, 
neuroinflammation and microglial activation; each of these manifestations lead to axonal 
degeneration and neuronal death, which impairs neuronal pathways and are likely to give 
rise to CTE symptoms 17,18. 
Tau protein is a protein that, in the normal state, is bound to microtubules in 
healthy axons and is crucial in regulating many normal cellular functions including 
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microtubule polymerization and structure, axonal transport, and crosslinking individual 
microtubules into well-organized, evenly spaced bundles 19. Under normal conditions 
where stretching of the neurons is moderate, tau proteins help the microtubules maintain 
their structure, stretch intact, and deform reversibly. However, a traumatic hit to the head 
can cause pathological conditions with high stretching and high stretch rates. This 
abnormal stretching disrupts tau-microtubule interactions making the axons brittle and 
damages the cytoskeleton. With a damaged cytoskeleton, axonal transport is hindered 
creating a buildup of transport products, swelling of the axon and breakage. Upon 
breakage, there is a resection of the axon from the site of transection to the cell body. 
This swelling that develops can be seen microscopically and is a classical hallmark of 
diffuse axonal injury, which is seen throughout CTE 19. 
Furthermore, following a mTBI and neuronal damage the tau becomes 
hyperphosphorylated— likely due to an imbalance between kinases and phosphatases 
within the cell. Hyperphosphorylation of tau reduces its affinity to microtubules, leading 
to the destabilization of microtubules, which exposes more phosphorylation sites, and 
eventually leads to the clumping of p-tau into oligomers. These oligomers then undergo 
additional cellular modifications to form neurofibrillary tangles (NFT), which are 
pathological hallmarks of CTE 17. NFT’s can further grow, causing a decrease in cellular 
organelles, impairing cellular activities, leading to cell death17. Although it is uncertain 
whether the p-tau oligomers or NFTs are the cause of neurodegeneration, there is strong 
evidence that these both effect the synaptic and axonal dysfunction as well as neuronal 
loss, which are what lead to the neuropsychological symptoms seen in CTE 17,19,20. 
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Additionally, it is well established that CTE is a progressive neurodegenerative 
disease, but the mechanism of cellular transmission still remains uncertain. Since CTE 
progresses gradually over time, it can be deduced that biochemical and cellular factors 
modulate its pathology rather than the immediate biomechanical factors that result from 
injury. However, since CTE develops at certain focal points throughout the brain suggests 
that the biomechanical forces are what trigger the local initiation and the development of 
the disease at those specific locations 19.  
During traumatic brain injury, the brain is subject to rapid acceleration, 
deceleration, and rotational forces. These forces will cause the brain to elongate and 
deform, stretching the micro-architecture of the brain, including neurons (predominantly 
long fibers), glial cells, and blood vessels 17. Studies have shown that the areas that 
experience the most significant effects of forces are at locations where a change in tissue 
density occurs, like the white-grey matter interface, perivascular areas, and depths of the 
sulci 18,21–25. The highest concentration of p-tau and diffuse axonal injuries are most often 
found at these areas of highest stress, and it is at these areas of pathology that help with 
diagnosis 19. Additionally, the white-grey matter interface is where the foci of CTE 
pathology begins along with diffuse axonal injury, supporting the claim that 
biomechanical factors modulate the foci of CTE.  As the disease progresses the pathology 
spreads from these local epicenters to the superficial layers of the adjacent cortices, then 
throughout the brain to the frontal and temporal lobes, diencephalon, and brainstem 18.  
It has yet to be completely understood how the disease spreads, but there has been 
some insight. The tau phosphorylation and misfolding are potentially reversible 
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processes, meaning up through stage I or possibly stage II the disease has the potential to 
be reversible or non-progressive in some cases. It is possible that the tau pathology is 
spread both intracellularly and extracellularly through the brain. This interneuronal tau 
transmission has been suggested to be mediated by a prion-like templated misfolding of 
tau. Additional methods of spreading may be via neuronal synapses, astrocytes, 
microglia, and CSF pathways 18. 
Aggregation of TAR DNA-binding protein 43 (TDP-43), normally a nuclear 
protein, is also found in CTE and is seen in all CTE cases by the later stages. During 
mTBI, TDP-43 expression is upregulated, which leads to its translocation from the 
nucleus to the cytoplasm, followed by hyperphosphorylation, ubiquination, cleavage, and 
eventual aggregation of the protein. This abnormal aggregation becomes neurotoxic and, 
similar to p-tau, has been shown to have prion-like and propagation properties, allowing 
it to spread throughout the brain 17. 
There is also microglial activation that occurs in the disease as a result of 
mechanical trauma and disruption to the blood brain barrier. After an initial injury, the 
microglia become prepared or ‘primed’, but it isn’t until additional incidence of mTBI 
fully activates the microglia 26. Upon activation, cytokines, reactive oxygen species, and 
excitotoxins are released, all of which are believed to lead to neurodegeneration. With no 
additional injury, microglia can eventually switch from neuro-destructive action to a 
reparative action; however, with continued mTBIs, microglia are chronically activated 
leading to chronic neuro-inflammation and tissue injury that is seen in CTE 27. To note, 
the excitotoxicity (pathological overactivation) from microglial activation may play a role 
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in tau hyperphosphorylation as well 17. Furthermore, there is evidence showing that 
neuronal loss and misfolded proteins can further prime microglia and may perpetuate the 
disease process 26.  
Lastly, amyloid beta (Aß) and lewy body pathology appears to modulate the 
disease’s course.17 Stein and colleagues found that Aß deposition is altered and 
accelerated in CTE subjects compared to normal aging and that those with both Aß and 
CTE have a more severe pathology and worse clinical outcomes independent of age 28. 
They also found that around 50% of the patients they studied had Aß pathology. 
According to McKee, alpha-synuclein positive Lewy bodies have been found in about 
20% of CTE cases 22. This may be attributed to synergistic interactions between tau and 
alpha-synuclein pathologies 17,29. 
CTE is also associated with the development of other neurodegenerative diseases. 
Of 177 neuropathologically confirmed cases of CTE, the largest case series of CTE in 
American football players, 19% had comorbid Lewy body disease, 13% with 
Alzheimer’s disease (AD), 8% with frontotemporal lobar degeneration, and 6% with 
Amyotrophic Lateral Sclerosis 16. In another study of 142 neuropathologically confirmed 
cases of CTE, 10.6% had comorbid motor neuron disease, 10.6% had AD, 7% had Lewy 
Body disease, 2% had frontotemporal lobar degeneration and 4.5% had two or more of 
these comorbidities; 63.2% of the cases were diagnosed only with CTE 18. The frequency 
of all of these comorbidities in both studies also increased with age. In addition to the 
diseases listed, motor neuron disease is another comorbid neurodegenerative disease that 
is commonly seen in CTE cases 16. Lastly, four of five veterans with early stage CTE 
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were also diagnosed with posttraumatic stress disorder, which suggests the possibility 
that PTSD may share biological and pathological components with CTE as well 18,30. 
Since TBI and repetitive head impacts may also be risk factors for these other 
neurogenerative diseases, a history of these may be a contributing factor to their 
coexistences15,31. 
 
Gross Pathology 
In early stages of CTE there are few, if any, identifiable changes in the brain. If 
there are changes present, it may appear as a cavum septum pellucidum, mild 
enlargement of the frontal and temporal horns of the lateral ventricles, or prominent 
perivascular spaces in the white matter, particularly in the temporal lobe. As the disease 
progresses to intermediate and advanced stages, changes become more apparent. 
Observed is a reduction in brain weight due to both gray and white matter atrophy, which 
is usually the most severe in the frontal and anterior temporal lobes. Furthermore, there is 
enlargement of the lateral and third ventricles, cavum septum pellucidum, septal 
perforations, atrophy of the several structures including the thalamus, hypothalamus, and 
mammillary bodies, thinning of the isthmus of the septum corpus callosum, and pallor or 
depigmentation of the locus coereleus (LC) and substantia nigra. Neuronal loss, grey and 
white matter atrophy, and ventricular enlargement are the result of the disease’s 
progression. It is rare to see any cerebellar abnormalities on a macroscopic scale 18,22. 
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Microscopic Pathology 
Early stage CTE can be characterized by the deposition of hyperphosphorylated 
tau (p-tau) protein as NFTs, astrocytic tangles and neuropil threads (NT) that manifest 
perivascularly along small blood vessels and at the depths of the cortical sulci. This 
specific, irregular and perivascular pattern of p-tau is distinct and is the basis for 
distinguishing the disease from other tauopathies, including AD 18,22. Axonal injury, 
axonal degeneration, myelin degeneration and white matter loss is common in early 
stages of CTE and can be seen as multifocal breaks (called varicosities) in the axons. 
These abnormalities may play a critical role in initiating p-tau pathology; this is 
supported by evidence of the degree of axonal injury paralleling the severity of the 
neurodegeneration 18,22.  
In later stages of CTE, p-tau pathology becomes widespread throughout the brain 
and is present in white matter. The protein becomes particularly dense in the medial 
temporal lobe structures, diencephalon, and brainstem. This widespread development 
leads to prominent neuronal loss, gliosis, and neuroinflammation. There is also severe 
axonal loss in later stage pathology 2,22,32.  
Abnormal accumulations of TDP-43 are also present in most (>85%) CTE cases 
and are partially colocalized with the p-tau protein. In the early stages, there are usually 
small amounts of TDP-43 positive neurites in the cortex, medial temporal lobe, and 
brainstem. The TDP-43 distribution in later stages include intraneuronal and intraglial 
inclusions in the frontal subcortical white matter and fornix, brainstem, and medial 
temporal lobe 32. 
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It is important to point out that beta amyloid (Aβ) containing plaques, which are 
characteristic of AD, are not consistently found in cases of CTE. Although they are 
present in some cases, they have not been found in early stage disease, unless the 
individual was over the age of 50 years old. Important in this distinction is that Aβ are 
significantly associated with age at death 22. Aβ have been found in 19% of subjects with 
stage II CTE who were over the age of 50. As discussed previously, Aβ pathology is 
synergistic with p-tau pathology, causing it to occur at an earlier age and accelerated rate 
in CTE than in a normal aging population. Aβ deposition is also associated with 
increased clinical and pathological severity 18,28.   
 
Staging of Pathology in CTE 
Currently, the only way to diagnose CTE is via postmortem neuropathological 
examination of the tissue 18. CTE diagnosis can be microscopically characterized into 
four distinct stages, each stage resembling the pathological severity. Stages I and II are 
considered mild pathology whereas stages III and IV are considered severe. The four 
stages were identified by McKee and colleagues after examining 68 cases of CTE 22. To 
note, the severity of pathology correlates with the duration of both football and boxing 
careers as well has years since retirement from athletics and age at death 33. 
Stage I CTE brains contain one or two isolated epicenters of NFTs and CTE 
lesions (dot-like and grain-like neurites) around small blood vessels at the depths of the 
cerebral sulci. These perivascular epicenters are most often located in the frontal, 
temporal, parietal, insular, or septal cortices. There may also be some p-tau 
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immunoreactive glia and glial processes. There can also be tau pathology found in the 
locus coereleus at this stage 18. The most common stage I symptoms include headaches 
and attention deficits, along with memory dysfunction, depression, explosivity, and 
aggression 22. 
In stage II there will be three or more CTE lesions at the sulcal depths of the 
cortex, scattered NFTs in the superficial laminae of the sulcal wall and gyral crests in 
adjacent cortices, and NFTs in the locus coereleus and nucleus basalis of Meynert 18. 
Depression, suicidality, and cognitive and memory dysfunctions become common in 
stage II and continue to manifest through the more severe stages 22. 
Stage III CTE is characterized by confluent patches of p-tau immunoreactive 
neurons and astrocytes centers surrounding blood vessels at the sulcal depths as well as in 
the superficial laminae of the cortex. NFTs are also found in the hippocampus, entorhinal 
cortex, amygdala, substantia nigra, dorsal and medial raphe, and olfactory bulbs. Also 
present is neurofibrillary degeneration in the several parts of the hippocampus 18. 
Symptoms emerging in stage III are behavioral issues like aggression and explosivity, as 
well as mild dementia 22. 
In stage IV NFTs and CTE lesions are densely distributed throughout the cerebral 
cortex, diencephalon, brainstem, cerebellar dentate nucleus, and spinal cord. There is 
often marked neuronal loss, in the frontal and temporal cortices, and astrocytic p-tau 
pathology. The primary visual cortex is usually unaffected in CTE 18. 
Severe dementia and more pronounced aggression, explosiveness, and paranoia become 
apparent in stage IV CTE, along with the previously mentioned symptoms 22. 
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Clinical Presentation 
CTE has been neuropathologically confirmed in a wide demographic range of 
cases. The youngest confirmed case of CTE was in a 17-year-old, but it has also been 
confirmed at all ages34. Athletes with high repetitive impact exposure, including those of 
boxing, American football, ice hockey, wrestling, lacrosse, rugby and soccer, as well as 
non-athletes with repetitive head impact exposure, including epileptics, developmentally 
disabled individuals who head bang, and victims of physical abuse, have been diagnosed 
with CTE 34,35. Early stage CTE has also been confirmed in military personnel exposed to 
repetitive mTBI from explosive blast injuries and repetitive concussion as well as 
advanced CTE after TBI sustained during military service18,30. Although head impacts are 
necessary to cause CTE, they are not sufficient. There are many additional risk factors 
that influence the development of the disease including genetics, but most still remain 
unknown 32. 
Symptoms typically present long after exposure to trauma and are distinct from 
acute concussion or post-concussion sequelae 22,32,36. Clinical features fall into four 
different categories: behavioral, mood, cognitive, and motor. Behavioral features often 
present as impulsivity, explosivity, and aggression. Mood symptoms typically present as 
depression, anxiety, irritability, and hopelessness. Common cognitive symptoms are 
memory impairment, executive dysfunction, and dementia in severe cases. Motor 
dysfunctions appear in a subset of cases, most often in former boxers. These symptoms 
include parkinsonism, ataxia, and dysarthria. Sometimes individuals with CTE 
experience chronic headaches 22,32,34,35. There has also been neuropathologically 
 17 
confirmed cases of CTE of individuals who presented asymptomatic, which is common 
in other neurodegenerative diseases as well 37. 
In recent years there has been a differentiation between “classic” CTE and 
“modern” CTE. Classic CTE, typically found in earlier cases of former boxers, is 
described as having more prominent motor features like gait disturbance, dysarthria, and 
pyramidal problems and lacking progressive cognitive, behavioral, or mood changes 35. 
On the other hand, modern CTE, found mostly in football players after 2005, is 
characterized by mood and behavioral changes with progressive cognitive dysfunction 
and dementia while lacking motor features 35. However, the distinction between these two 
disease types is most likely due to the differences in the biomechanics of the head impact 
dynamics between boxing and football. Boxers experience more rotational acceleration 
than football players and have greater impact on midbrain structures and the cerebellum, 
which can account for the motor symptoms seen in classic CTE32,35,36. 
Two distinct clinical presentations of CTE have been identified. The first type 
(mood/behavioral) initially exhibits mood and behavioral symptoms earlier in life with a 
mean age of approximately 35, and progresses to include cognitive symptoms later in the 
disease course 32. In a study by Stern and colleagues, this behavioral-type group of 
individuals reported to be more explosive, out of control, physically and verbally violent, 
and depressed than those presenting with the second type 36. The second clinical 
presentation (cognitive-type) begins with cognitive impairment later in life with a mean 
age of approximately 60, and can progress to include mood and behavioral symptoms 32. 
In the same study mentioned, the cognitive subjects typically had impaired episodic 
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memory, were likely to progress to dementia, and significantly older at the time of death 
36. Furthermore, results from the largest, and most thorough, CTE case series ever 
described were consistent with these conclusions 16. 
Suicidality and suicide is prevalent in many pathologically-validated cases of 
CTE (ranging from 10-29% between cohorts), but its association to the disease has yet to 
be understood 16,22,36,38–40. Actually, in the study of the largest case series of CTE to date, 
the most common cause of death for participants with mild CTE was suicide (27%) 16. 
Some studies have indicated an association between CTE and suicidality, but selection 
bias of cases of the disease complicates the analysis 32,38. Furthermore, suicide is a 
multifactorial and highly complex psychiatric issue with many different risk factors that 
are often comorbid in CTE cases, including but not limited to drug or alcohol use, 
psychiatric issues, performance enhancing drug use. All of these risk factors can lead to 
personality changes and neuropsychiatric abnormalities that make it difficult to determine 
the true risk of suicide 38. Additionally, in a recent study, it was determined that 
individuals with medical contact for TBI (including mTBI) compared with the general 
population without TBI, had increased suicide risk. TBI history, recent injury, and more 
numerous postinjury medical contacts for TBI were factors in determining suicide risk 41. 
With this information in mind and due to the lack of understanding the association 
between suicide and CTE, it is imperative to further investigate this topic. 
Overall, insight into the clinical presentation of CTE is limited due to the long 
progressive nature of the disease, the lack of in vivo diagnosis, and the use of 
retrospective reviews of case reports or family interviews. These limitations warrant 
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further prospective and longitudinal research of the disease to better understand its 
implications and symptoms. 
 
Risk Factors for CTE 
As mentioned previously, repetitive head impact may be a necessary risk factor 
for the development of CTE, but this alone is not sufficient to initiate the pathological 
disease. However, many risk factors still remain unknown due to the lack of in vivo 
biomarkers for diagnosis and the delayed onset and long duration of disease progression 
42. Some individuals have even remained asymptomatic despite discovering CTE 
pathology in them postmortem 34. Possible factors include age, genetics, medical and 
lifestyle history, and specific head trauma variables (location and severity of impacts, 
interval rest between impacts, frequency, magnitude, etc.) 36. There is not much known 
about these risk factors and their interactions with one another. The minimum exposure 
of repetitive head impacts needed to increase risk of CTE remains unknown as well and 
many of the factors may vary between individuals.  
All cases of neuropathologically verified CTE have been associated with 
repetitive mild brain trauma 18. It is not necessary for the trauma to be concussive as there 
have been numerous studies of individuals with varying types of exposure without history 
of concussion to still be diagnosed with CTE.34,43 In fact, as part of a study done by Stein 
and colleagues, it was revealed that the number of years of exposure, not the number of 
concussions, was significantly associated with worse tau pathology in CTE 43. These 
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findings suggest that the repeated and continued nature of head trauma, regardless of 
concussive symptoms, is the most important driver of disease 43.  
Age may also be a risk factor for developing CTE. Increasing age correlated with 
worsened CTE pathology in a study done by McKee and colleagues on 68 contact sport 
athletes with confirmed CTE 22. Additionally, the study done by Mez and colleagues on 
177 deceased tackle football players with CTE showed that the median age at death of 
participants with mild CTE pathology was 44 years, whereas the median age for 
participants with severe CTE pathology was 77 years 16,34. Earlier age of first exposure to 
repetitive head impacts may disrupt neurodevelopmental processes and increase 
vulnerability to long-term neurobehavioral disturbances 44,45.  Studies have shown that 
symptomatic former NFL players who started playing tack football before the age of 12 
had worse cognitive performance and altered corpus collosum white matter compared to 
those who began playing tack football at the age of 12 or older. Younger age of first 
exposure to tackle football has also been shown to be correlated with smaller thalamic 
volume in symptomatic players 46. Additionally, a study on 214 former football players 
showed that younger age of first exposure to football, before age 12 in particular, was 
associated with increased odds for impairment in self-reported neuropsychiatric and 
executive function 47.  
However, from a sample of 246 tackle football players it was found that age of 
exposure was not associated with CTE pathological severity, but it was associated with 
earlier neurobehavioral symptom onset, and was independent of level of play 48. 
Although the effect early exposure to repetitive head impacts is still largely unknown, 
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these studies suggest that incurring repeated head impacts during a critical 
neurodevelopmental period may increase the risk of later-life cognitive impairment 34. 
Other factors, including frequency and magnitude of hits, duration of exposure, player 
position, cumulative hits, type of exposure, and linear and rotational acceleration of hits, 
may also have an influence on development of CTE pathology and symptoms, but further 
research is still needed 16. 
Certain genetic polymorphisms may also increase susceptibility to CTE 34. The 
APOE e4 (APOE) allele has been shown to have some symptomatic and pathological 
associations. In a study of 30 former high exposure boxers it was discovered that the 
APOE allele may be associated with increased severity of chronic neurologic deficits 49. 
In a study of 53 active professional football players, older players with an APOE allele 
had lower cognitive performance than comparably experienced players without an APOE 
allele 50. However, APOE did not appear to be a risk factor for the development of CTE 
or the severity of CTE pathology in the autopsy series of 85 subjects with histories of 
repetitive mild traumatic brain injury 22. Although in a subset of this series, the proportion 
of APOE homozygotes were higher than expected and the proportion was higher in those 
who presented with cognitive dysfunction compared to those who presented with 
behavioral or mood dysfunction 51. 
In a study done by Cherry and colleagues on 86 deceased male athletes who had 
played American football, it was discovered that a variation in transmembrane protein 
106B (TMEM106B) may have a protective effect on CTE-related outcomes. In the 
analysis the minor allele of TMEM106B was associated with both reduced p-tau 
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pathology and neuroinflammation in the dorsolateral frontal cortex (DLFC) as well as an 
increased synaptic protein density. The minor allele was also associated with reduced 
ante-mortem dementia. These results demonstrate that the TMEM106B genotype is one 
possible explanation for the variance seen in severity of CTE-related outcomes despite 
similar exposure to contact sports 52.  
There are several other factors that may also contribute to the clinical presentation 
of CTE including, but not limited to, race, cardiovascular disease, pain, headaches, diet, 
lack of physical activity, alcohol and substance abuse, and difficult post-professional 
contact sport psychosocial adjustment 34. Cognitive reserve and flexibility may also be 
protective against clinical manifestations of CTE 36,53. 
 
Biomarkers and Treatment 
Since CTE can only be diagnosed through neuropathologic examination, there is a 
strong need to develop in vivo biomarkers for CTE. Biomarkers would help improve our 
understanding of the disease mechanisms, preventions, and treatments. There has been 
some progress on this discovery, however there is still no established neuroimaging 
markers, fluid markers, or treatment for CTE 54. 
Currently, there are several possible fluid biomarkers that are being investigated. 
Plasma T-tau has been shown to be positively associated with an estimate of cumulative 
repetitive head impacts in a study of 96 symptomatic former NFL players and 25 same-
age controls, but did not show clear between-group differences 55. Furthermore, in a study 
on 68 former NFL players and 21 controls, Alosco and colleagues found that repetitive 
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head impacts were positively associated with cerebrospinal fluid T-tau in NFL players 56. 
This study also reported that higher sTREM2 levels (a possible CSF biomarker of CTE 
microglial activation) were associated with higher T-tau concentrations, which further 
strengthens the relationship between microglial activation and neuronal injury along with 
exposure to RHI and CSF t-tau 56,57. Additionally, tau-positive exosomes in plasma has 
potential to be used as a CTE biomarker. In a study of 78 former NFL players and 16 
same age controls, Stern and colleagues found that higher exosomal tau was associated 
with worse performance on tests of memory and psychomotor speed, which are 
symptoms common to CTE 58. In a recent study by, Cherry and colleagues, CCL11, a 
chemokine protein that is associated with age-associated cognitive decline, is observed to 
be increased in the brain and cerebrospinal fluid in CTE (more so than in AD). This 
evidence suggests CCL11 as a potential target for future CTE biomarker studies 59. 
Some neuroimaging techniques that are currently being investigated include 
positron emission tomography (PET) ligands for p-tau and neuroinflammation, magnetic 
resonance spectroscopy (MRS), diffusion tensor imaging (DTI), magnetic resonance 
imaging (MRI) detection of specific structural abnormalities common in CTE, and 
functional MRI measuring specific patterns on connectivity 42,58. PET could provide most 
direct in vivo marker of CTE after further studies. Both markers in PET and MRS of 
neuroinflammation and microglial activation may be able to provide insight into 
mechanisms of CTE. DTI studies, which reflect white matter abnormalities, may be able 
to help confirm if the damage is chronic or progressive and if it is associated with the 
tauopathy of CTE 42. 
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Locus Coeruleus 
To advance the research on CTE we must continue to search for the underlying 
pathophysiology and mechanisms of the disease as well as specific locations within the 
brain that may be affected throughout each stage. The locus coeruleus (LC) is a heavily 
pigmented nucleus in the pons of the brainstem that provides the main source of 
norepinephrine to the entire brain. This nucleus is critical to normal functioning via 
modulation and control of arousal, attention, and memory. Dysfunction of the locus 
coeruleus has shown to cause a wide array of symptoms, many of which are similar to 
those seen in CTE. Locus degeneration is actually seen in several neurodegenerative 
diseases like Parksinson’s disease (PD) and AD. Research also suggests that the locus 
coeruleus is one of the first areas in AD to degenerate and is partially responsible for the 
progressive or widespread nature of the disease 60. Similarly, there has been evidence 
implicating the locus coeruleus in CTE 18,22. 
The LC is a small bilateral collection of about 10,000-15,000 norepinephrine-
producing neurons located in the dorsal wall of the rostral pons in the lateral floor of the 
fourth ventricle 61. Although small, the LC is the major provider of norepinephrine to the 
entire central nervous system (CNS). Neurons of the LC project extensively throughout 
the entire CNS to areas including the forebrain, brainstem, cerebellum, and spinal cord. 
These projections of the LC-NE system are widespread, yet selective and highly 
complex, and are responsible for modulating numerous behavior and cognition including 
sleep/wake states, attention, memory, and stress responses 61,62. 
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When norepinephrine is released, it exerts potent neuromodulatory effects on 
synaptic transmission, which affects the membrane potential and excitability of neurons 
as well as synaptic plasticity throughout the brain, giving rise to the LC-NE system 
effects. Norepinephrine released in extrasynaptic sites may also regulate other neurons, 
astrocytes, and microvessels, which can affect metabolism and signaling in astrocytes, 
control local blood flow, and aid in expression of inflammatory cytokines and nitric oxide 
in astrocytes and microglia 63,64. 
The LC mainly releases norepinephrine throughout the CNS, but also contains subsets of 
neurons that co-release a wide variety of other neurotransmitters and neuromodulators 
including vasopressin, somatostatin, neuropeptide Y, enkephalin, neurotensin, 
corticotropin releasing factor, and galanin 65. The co-release of these peptides with 
norepinephrine may alter the properties and condition of the LC’s activation. The peptide 
transmitter galanin, for example, is expressed in up to 80% of neurons helps the LC 
modulate a variety of behaviors such as wake/sleep states, nociception, feeding, and 
parental behavior 66,67. 
The anatomical connectivity of the LC to the rest of the brain is crucial for its 
diverse range of functions. The LC can be thought of as the brain’s “watchtower” as it 
scans incoming sensory information for important events that require immediate attention 
68. Neurons from the LC send axon collaterals to multiple targets that process the same 
sensory information 63. Activity of the LC closely correlates with level of arousal 69. The 
LC extensively innervates all hemispheric lobes in the cerebral cortex where it is the sole 
source of norepinephrine, making it critical for higher cognitive and affective processes 
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61. LC efferent fibers are most active during wakefulness to help increase cortical 
activation 70. The LC innervates the basal forebrain (medial septal area, medial preoptic 
area, substantia innominate) as well in order to modulate the sleep-wakefulness state 71. 
Other LC efferents also inactivate sleep-promoting neurons (GABAergic neurons) to 
further promote wakefulness 71,72. 
The LC is also critical in maintaining arousal via the forebrain thalamocortical 
circuits. In anticipation of waking and waking-associated forebrain activation, there is an 
increase in LC neuronal firing rates, which has been shown to help promote the waking 
state. Additionally, the LC will prevent abrupt transition from wakefulness to sleep and 
promote optimal behavioral performance by modulating the transfer of sensory 
information to the cerebral cortex. LC also provides inhibitory inputs to the 
hypothalamus to further regulate the sleep-wakefulness state and maintain arousal 73. 
Additionally, outputs to dorsal raphe nucleus increase neuron firing and further promotes 
wakefulness 74. Overall, many norepinephrine projections from LC help promote 
wakefulness and arousal. 
The LC modulates attention as well. NE release tonically activates 
thalamocortical neurons, which is critical for acute transferring of sensory information to 
the cerebral cortex during wakefulness 75. Furthermore, the reciprocal projections to and 
from specific cortical areas enables transitions between behavioral states and facilitates 
focused attention, impulse control, and accurate task performance 76. The LC-NE system 
may also help suppress the ventral frontoparietal network to prevent reorienting to 
distracting events 77. The complex sensory input to the LC is also critical for vigilance 
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and efficient processing of significant information 61. This “adaptive gain” theory 
proposed by Aston-Jones and Cohen suggests the LC-NE system integrates sensory, 
attentional, and memory processing by modulating certain signals during the processing 
of salient events. This is believed to facilitate subsequent behaviors and optimize task 
performance on both short and long timescales 76. 
The LC densely innervates the amygdala to modulate autonomic and behavioral 
responses to stressful stimuli and induce fear and anxiety responses 74. In a study by 
McCall and colleagues, it was shown that activation of the LC during stressful stimuli 
may elicit anxiety-like and aversive behaviors. This study also showed that inhibition of 
the LC during the stressful stimuli prevented subsequent anxiety-like behavior 78. During 
stress, there is also increased tonic rates of NE release in the prefrontal cortex, which may 
help explain impairment of attention during stress and other states of high arousal 79. 
Additionally, the level of arousal, which is highly correlated to LC activity, determines 
the likelihood of a memory being encoded and retrieved80. The LC-NE system modulates 
memory including episodic, working, and emotional memories 60. 
LC innervation to the amygdala has also shown to help with forming and 
retrieving emotional responses and memories. Abnormal activation of the amygdala and 
the LC has shown to be implicated in post-traumatic stress disorder 63,74. The LC actually 
provides sole projections of NE to the hippocampus and helps contribute to formation, 
and possibly retrieval, of declarative memories via these projections 61,81. Norepinephrine 
acting on the prefrontal cortex actually exerts potent modulatory influence on working 
memory 63,79. NE interacts with other neurotransmitters and stress hormones in 
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hippocampus and amygdala to promote memory consolidation and retrieval in response 
to contextual cues 63,82. 
The cerebellum also receives LC projections, especially within the cerebellar 
cortex. These projections alter one or more of the functions of cerebellum including 
planning, coordination, learning of movements, and cognition and emotion 81,83–85. 
Depletion of NE from cerebellum has been found to result in impaired motor 
performance 86. LC has also been shown to influence processing of sensory information 
via projections to dorsal horn neurons, which are sensory neurons associated with 
detection of pain, temperature, touch, and proprioception81,87. Projections from LC have 
shown to have analgesic properties 88. Additionally, projections from the LC to the 
thalamus may also be involved in modulation of pain 89. 
The LC also has a wide array of inputs from afferent fibers which originate from 
parts of the cortex, amygdala, hypothalamus, spinal cord, other areas in the brainstem, 
and spinal cord. Recent tracing method studies have shown that up to 111 different brain 
regions send direct input, with varying number of input neurons, to the LC. Individual 
LC-NE neurons receive input from at least 9-15 different brain regions 62,90. 
Correspondingly, the LC has numerous types of neurotransmitter receptors, which allows 
for the wide array of inputs and underlies its regulatory diversity 61. Regulation of LC 
activity is coordinated by many different subcortical and cortical afferents feedback loops 
that reciprocally drive activity of those structures. For example, there is a strong 
reciprocal connection between the LC and the prefrontal cortex, which is responsible for 
executive functions like cognition, memory, attention, and vigiliance81. The interplay of 
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the LC’s afferent and efferent fibers create a feedback and neuromodulary system which 
is important to its various and complex roles. The LC has a critical role as a modulatory 
nucleus to numerous structures throughout the CNS to ultimately control of a wide 
variety of functions including attention, cognition, and memory. Disruption of the LC has 
been shown to cause symptoms related to these functions, the same ones that are 
implicated in aging, as well as CTE and various other neurodegenerative diseases and 
psychiatric dysfunctions. 
 
Locus Coeruleus Pathology in Neurodegenerative Diseases 
During normal aging, there is loss of LC neurons, which has been shown to have 
an impact of arousal, attention, and memory 60. There is clear evidence that LC tau 
pathology increases with age 91. Furthermore, there are a number of neurodegenerative 
diseases that have pathological changes in the LC including, AD, PD, Lewy body 
disease, amyotrophic lateral sclerosis, multiple sclerosis, and CTE. The LC is actually 
affected early in these diseases and causes many of the symptoms seen in their early 
courses 92. The LC neurons may be especially vulnerable to synucleinopathies and 
taupoathies due to their high bioenergetic need, which can increase the nucleus’ oxidant 
stress 93. The LC also has extensive exposure to central nervous system capillaries and is 
in close proximity to the fourth ventricle, which may expose it to toxins from the blood 
and cerebrospinal fluid, respectively 94,95. 
In PD, the degeneration of the LC noradrenergic neurons occurs earlier than 
dopaminergic neurons in the midbrain and is what is responsible for the characteristic 
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motor symptoms of PD 96.  Additionally, early cognitive changes, dementia (in advanced 
cases), sleep disturbances, and emotional changes like depression all are likely caused by 
LC neuronal degeneration as well 81,97–100. The noradrenergic neurons from the LC appear 
to have a neuroprotective effect on the dopaminergic neurons of the substantia nigra, 
which are principally responsible for PD pathology 69. 
There is also strong evidence that dysfunction within the LC is important to the 
development of AD. P-tau accumulation and degeneration in the LC actually occurs in 
the earliest pathological stages, it occurs gradually along the neuropathological 
progression, and there is significant loss of noradrenergic LC neurons that can be seen in 
post-mortem examination 69,92,101. Neuronal loss in the LC has been correlated to 
increased cortical amyloid plaque and NFTs in AD 102. Increased NFTs have been shown 
to correlated with poorer performance on measures of cognitive function 101. LC 
degeneration has been implicated in the cognitive symptoms of AD, both during the early 
stages and as it manifests into dementia 101,103,104. NE decline in AD may also accelerate 
the course of the disease 94,105. Furthermore, reduced alertness, sympathetic activity, and 
arousal have also been implicated in AD as a result of LC neuronal degeneration 69. 
Degeneration of wake-promoting LC neurons may partially explain the sleepiness during 
the day 106. Depression is common in AD and has also been shown to be related to the 
neuronal loss in the LC 107. Norepinephrine released from the LC also helps to protect 
neurons from damage like inflammation and excitotoxicity, which are factors in 
neurodegenerative diseases like AD and CTE 60. Overall, degeneration of the LC-NE 
system is a cardinal feature of AD pathogenesis and plays a major role in the 
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pathogenesis and progression of the disease 68. To note, the differences in symptoms 
noted between diseases is caused by differential topographical degeneration of neurons 
within the LC108. 
The LC has also been implicated in CTE, but there have been no studies 
examining LC pathology in relation to the disease progression or its symptoms. As noted, 
the LC is critically important for a wide variety of CNS functions, many of which often 
present as dysfunctions in CTE. Pathology is seen in the earliest stages of CTE and 
continues to be seen in each of the subsequent stages, rendering it important to the 
disease progression. At the gross level there is depigmentation of the LC and, 
microscopically, NFT and neurites are found in the LC during from stages I through IV 
18. However, little is known about the specific role LC pathology plays in CTE and its 
symptoms. LC pathology is currently only a supporting factor that is evaluated for 
disease staging, but with further insight, it has the potential to be a more significant factor 
for diagnosing stages. Furthermore, given the effect of LC pathology in various other 
neurodegenerative diseases and the NE system, it is likely that the LC has a potential role 
in CTE progression and symptom development as well. Given the strong evidence 
linking the pathology, degeneration, and dysfunction of the LC and the NE system to a 
wide range of psychiatric dysfunctions, neurodegenerative diseases and their symptoms, 
it is critical that we evaluate the specific effects LC pathology has in CTE. 
In this study we aim to explore the pathology and subsequent clinical 
manifestations of the LC during CTE. We hypothesize LC CTE pathology should 
increase with the severity of CTE. Furthermore, increased CTE pathology in the LC 
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should create disturbances to the LC and the LC-NE system and manifest clinically. 
Specifically, LC CTE pathology may be associated with age of onset of general 
behavioral and cognitive symptoms as well as individual symptoms and outcomes 
including impulsivity, depression, depressed mood and death by suicide. Overall, we 
expect to see that increased LC pathology enhances the development of a wide range of 
symptoms which manifest in CTE. 
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METHODS 
Subjects 
A total of 341 brains from former athletes, military veterans, or civilians with a 
history of repetitive head injury who had donated to the VA-BU-CLF Brain Bank were 
neuropathologically evaluated for the changes of CTE, as well as other neurodegenerative 
conditions (AD, PD, dementia with Lewy bodies, frontotemporal lobe degeneration, 
motor neuron disease) using previously published selection criteria and protocols 109. 
Selection criteria was based on RHI exposure history with sufficient intensity so that 
there is reasonable chance for the development of CTE. If this was met, subjects were 
included regardless of whether symptoms were present. Subjects were excluded to 
prevent inclusion of brain and spinal cord specimens of poor quality 109. Of the total 
number of brains examined, 184 subjects were selected who had no comorbid diseases 
and did not lack the data examined in this analysis. All cases were male. “No CTE” cases 
were those with a history of RHI, but were not diagnosed with CTE.  
 
Table 1. Demographic and Exposure Characteristics of Subjects. 
CTE Stage N Age at death 
Age of first exposure to 
sports 
Years of 
exposure to 
sports 
No CTE 41 38.0 ± 19.2 10.1 ± 2.9 9.0 ± 4.2 
I 25 35.2 ± 14.0 8.8 ± 3.6 11.6 ± 4.8 
II 35 44.0 ± 17.0 11.2 ± 3.1 13.1 ± 4.6 
III 54 65.3 ± 12.6 12.6 ± 2.7 16.4 ± 5.0 
IV 29 75.5 ± 7.9 12.6 ± 2.6 18.6 ± 5.1 
Total 184                                                          
 
Data expressed as mean ± SD. 
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Clinical Assessment 
The Institutional Review Board at the Boston University Medical Campus 
approved all research activities including post-mortem clinical record review, interviews 
with family members, and neuropathological evaluation. Retrospective clinical evaluation 
comprised of a combination of online surveys and semi-structured telephone calls 
between researchers and the family members and close friends of the subject to obtain 
demographic information, repetitive head impacts (RHI) exposure, substance use, and 
medical, social, and family histories, with a particular focus on possible 
neurodegenerative conditions, including symptom presence, breadth, severity, and 
progression. Specific symptoms for this study investigated how often subjects 
demonstrated impulsivity, whether depressed mood was present for more than two 
weeks, diagnosis of Major Depressive Disorder based on the Diagnostic and Statistical 
Manual of Mental Disorders, 5th edition (DSM-5), and whether or not suicide was the 
cause of death 110. Behavioral neurologists and/or neuropsychologists with expertise in 
neurodegenerative disorders conducted clinical interviews to obtain a detailed medical 
and clinical history, including the presence, nature, and timeline of symptoms related to 
cognitive and neuropsychiatric function, as well as other neurological and medical 
histories and symptoms16. Researchers conducting these evaluations are completely 
blinded to the pathological examinations and findings 59,109. 
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Neuropathological Examination 
Pathological processing, immunohistochemistry, evaluation, and diagnosis were 
conducted using previously established methodology for the BU, ADC, and CTE brain 
bank 109,111. Neuropathological diagnosis of CTE was made using validated criteria for 
diagnosis and stages of CTE and criteria recently defined by the 2015 NINDS-NIBIB 
Consensus Conference 22,112. Other neurodegenerative diseases were diagnosed using 
well established criteria for each disease. Pathological evaluation and diagnosis occur 
without any knowledge of the subject’s RHI or clinical history and are confirmed by two 
neuropathologists. A neuropathology report is generated that includes a description of the 
macroscopic and microscopic findings and a list of pathological diagnoses, including 
CTE stage 109. 
 
Immunohistochemistry 
All brain tissue was processed identically by fixation in periodate-lysine-
paraformaldehyde (PLP) and stored at 4℃. During initial processing, macroscopic 
features and brain volume were recorded. Tissue was blocked and cut at 10 μm thickness. 
Sections from multiple tissue regions, including one at the level of the LC, were stained 
for features of p-tau with monoclonal antibody AT8 using methods previously described 
by McKee et al 113. Antigen retrieval was performed by boiling sections in citrate buffer 
(pH 6.0) for 10 mins. Sections were incubated at 4 °C overnight with antibodies to 
various markers including anti-PHF-tau (AT8) (Pierce Endogen, 1:2000). Sections were 
treated with biotinylated secondary antibodies then labeled with a 3-amino-9-
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ethylcarbazol HRP substrate kit (Vector Laboratories). Sections were counter stained 
with Gill’s Hematoxlin (Vector Laborities H-3401) and coverslipped with Permount 
mounting medium 59.  
 
pTau Quantification 
Immunostained slides were scanned and digitized at 20× magnification using the 
Aperio ScanScope (Leica) as previously described 114. Using Leica image analysis and 
automated counting software, the Aperio color deconvolution algorithm was customized 
to determine total AT8 positive staining restricted to the highlighted areas. Each area was 
highlighted to closely encircle dorsally-located, bilateral groups of neuromelanin-
pigmented neurons that are representative of the LC. Portions within the encircled area 
were selectively deselected if artifact was present. If these features were not present, no 
area was highlighted. The pixel counting algorithm was modified to recognize positive 
AT8 staining while omitting neuromelanin. All quantifications were standardized to the 
area measured and presented as density of pixels per analyzed area, all of which is 
previously described 57,59. 
 
Statistics 
Statistical analysis was performed using SPSS (v.24; IBM, Inc., Armonk, NY) 
and GraphPad Prism. AT8 density was log-transformed to normalize for regression 
analysis to determine relationship with years of exposure. A t-test was performed to 
compare the mean density of AT8 positive pixels between CTE stage groups. An ordinal 
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regression analysis was used to determine the correlation between LC AT8 density with 
CTE stage. Multivariate regression analyses (controlled for age) were used to determine 
the correlation between LC AT8 density and age of CTE symptom onset, age of cognitive 
symptom onset, and age of behavioral symptom onset. One-way analysis of covariance 
(ANCOVA) controlled for age was used to compare AT8 density among groups for 
clinically relevant phenotypes including death by suicide, presence of depressed mood (at 
least one episode lasting at least two weeks), presence of Major Depressive Disorder 
according to criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th 
Edition (DSM-5) 110, and impulsivity (how often the subject demonstrated impulsive 
behaviors).  
 38 
RESULTS 
 
LC Tau pathology correlates with years of exposure to sports and severity of disease 
First, to determine if the observed LC tau pathology was related to a history of 
head trauma, we compared the number of years playing sports to the density of tau in the 
LC. An increase in LC AT8 density was significantly correlated with increased years of 
exposure (p< 0.001) (figure 1). This was further confirmed via multiple linear regression 
showing that years of exposure to sports was significantly correlated to LC tau density (β 
= 0.038, p < 0.001, CI = 0.17 - 0.058) independently of age at death (β = 0.030, p < 
0.001, CI = 0.25 - 0.036). LC AT8 density was significantly increased in stages III and 
IV when compared to cases with stages I and II or no CTE (p < 0.001) (Figure 2). There 
was no significant difference observed in LC AT8 density when comparing individuals 
with no CTE, stage I, and stage II. There was no significant difference between the LC 
AT8 densities in stage III or stage IV either. Using an ordinal regression analysis, LC 
AT8 density significantly predicted CTE stage (odds ratio=1.595, p<0.001, CI= 1.130 – 
2.059) independent of age at death (odds ratio=0.04, p<0.001, CI= 0.020 – 0.060). 
 
LC Tau pathology does not correlate with symptom onset or presence 
There was also no relationship seen between LC AT8 density and age of CTE 
symptom onset (β = -1.836, p = 0.222, CI = -4.798 - 1.125). When further stratifying the 
type of symptom present at disease onset, we still did not observe any relationship 
between age of cognitive symptom onset (p=0.400, β= -1.026, CI= -3.435 – 1.383) or age 
of behavioral symptom onset (p=0.219, β= -1.993, CI= -5.186 – 1.199) and LC tau 
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pathology. To further determine if LC tau pathology had any effect on specific clinical 
outcomes multiple depression related tests and outcomes were examined. Overall, 
ANCOVA analysis demonstrated that LC AT8 tau density did not significantly differ 
between individuals with CTE with or without meeting DSM-5 criteria for MDD (Figure 
3A). Additionally, no difference was observed between individuals who committed 
suicide and those who did not (Figure 3B). No difference was seen when comparing 
cases with and without depressed mood (Figure 3C). Finally, no difference in LC AT8 
tau pathology was seen in impulsivity frequencies (Figure 3D). 
 
Figure 1. LC AT8 density vs RHI exposure years. Total density of LC AT8 tau (log 
transformed) significantly increases as a function of years of exposure to RHI (p<0.001). 
Subjects duration of exposure ranges from about one year to more than 30. Data was 
analyzed using a linear regression model. Each dot represents one individual. 
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Figure 2. LC AT8 Density in CTE staging. Average AT8 density in LC in each disease 
stage controlled for age. Subjects with stage III and stage IV CTE had greater average LC 
AT8 density than those with stage I and II CTE and RHI with no CTE. There are no 
significant differences in LC AT8 density between no CTE, stage I, and stage II CTE. 
There are no significant differences in LC AT8 density between stages III and IV CTE. 
Data was analyzed using a one-way ANOVA, ***p<0.001. 
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Figure 3. LC AT8 Density differences between clinical symptoms. 
A. DSM-5 MDD: 62 no, 26 yes. There is no significant difference in LC AT8 density in 
those meeting criteria for DSM-5 MDD compared to those who did not (p=0.58). B. 
Death by suicide: 83 no, 21 yes. There is no significant difference in LC AT8 density 
between those who died by suicide compared to those who did not (p=0.068). C. 
Depressed mood: 36 no, 55 present. The data shows no significant difference in LC AT8 
density in those who presented with depressed mood compared to those who did not 
(p=0.12). D. Impulsivity: 14 never, 45 sometimes, 43 often. There was no significant 
difference in LC between LC AT8 density in those that never presented with impulsivity, 
sometimes presented with it, and never presented with it (p=0.16). Each figure was 
analyz ed using ANCOVA and corrected for age. 
No Yes
0
20000
40000
60000
A
T
8
 d
e
n
s
ity
 (
P
o
s
iti
v
e
 p
ix
e
ls
/m
m
2
) p = 0.58
N
ot
 S
ui
ci
de
S
ui
ci
de
0
20000
40000
60000
A
T
8
 d
e
n
s
it
y
 (
P
o
s
iti
v
e
 p
ix
e
ls
/m
m
2
)
p = 0.068
No Present
0
20000
40000
60000
80000
A
T
8
 d
e
n
s
ity
 (
P
o
s
iti
v
e
 p
ix
e
ls
/m
m
2
)
p = 0.12
N
ev
er
S
om
et
im
es
O
fte
n
0
20000
40000
60000
80000
A
T
8
 d
e
n
s
it
y
 (
P
o
s
it
iv
e
 p
ix
e
ls
/m
m
2
) p = 0.16
A 
B 
D 
C 
 42 
DISCUSSION 
 
This preliminary analysis demonstrated that density of p-tau in the LC increases 
with greater duration of exposure. LC p-tau density was also shown to be significantly 
less in those with mild CTE (stages I and II) compared to those with severe CTE (stages 
III and IV). The density of p-tau in the LC was also predictive of CTE stage when the 
analysis was controlled for age. This data suggests that LC pathology may be associated 
with the normal disease progression and is reflective of the severity of disease. The data 
also confirms that LC pathology is reflective of disease; however, it lacks information for 
distinguishing between each individual stage. On the contrary, this data presents a 
potential application for using the p-tau density in the LC to distinguish between both 
stages II and III or early or late CTE. Additionally, future studies should explore the 
reason why there is a significant difference between mild and severe stages; the reason 
may potentially be due to a gradual progression of the disease or a certain cascade during 
the transition from stage II to III is initiated within the LC or from its neuronal 
connections. This information may help determine how the disease progresses with 
increasing severity and the effect LC pathology has on the overall disease.  
This analysis also showed no correlation between density of LC p-tau and age of 
general CTE symptom onset, age of cognitive symptom onset, or age of behavioral 
symptom onset. This is interesting due to the fact that diagnostic criteria describe LC 
pathology early in disease staging of not only CTE, but other neurodegenerative diseases 
as well. LC is particularly vulnerable to neurodegeneration and is a key component in 
other neurodegenerative diseases115,116. In AD, for example, the LC pathology is a 
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prominent feature of prodromal disease that contributes to cognitive dysfunction. 
Actually, the early loss of LC projections appears to be central to AD and PD 
pathophysiology and contributes to its progression 115–117. The LC is heavily implicated 
AD and decreases in LC neuron numbers have been associated with increased 
postmortem neuropathology in this disease 115. Furthermore, the portion of the LC that 
projects to the cortex and hippocampus shows the greatest vulnerability in AD, which 
further underscores the significance of looking at the relationship between p-tau 
accumulation in the LC and both the hippocampus and parts of the cortex affected in 
CTE 118. Moreover, LC dysfunction and degeneration is evident in other 
neurodegenerative diseases including PD, Lewy Body disease, FTLD, and multiple 
sclerosis 116,119. Considering the significance of LC in multiple neurodegenerative 
diseases, additional studies should continue to evaluate the relationship between LC 
pathology and the onset of disease. 
A possible element for future evaluation may be whether the increased presence 
of p-tau in the LC has an effect on the development of the disease in the various locations 
of the brain where the LC projects to and are often implicated in CTE (i.e. amygdala, 
hippocampus, cortical regions). This could potentially be tested in animal tauopathy 
models with specific LC p-tau accumulation 120. As the tauopathy progresses within the 
animal model LC, it may be possible to identify specific neuropsychiatric symptoms 
resulting from regional LC neuronal damage. Increasing LC p-tau can also be compared 
to time of symptom development. Additionally, the effect of LC p-tau and LC 
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dysfunction can be evaluated with respect to progression of the tauopathy throughout the 
brain, specifically in regions implicated in CTE. 
LC p-tau density also did not show any significant relationship with any of the 
clinical symptoms we analyzed. There was no significant relationship founds between 
subjects with individual behavioral dysfunctions (depressed mood, MDD, death by 
suicide, and impulsivity) with LC p-tau density. However, there is evidence that 
pathology in the LC likely manifests into clinical symptoms seen in other 
neurodegenerative diseases. Both AD and PD pathologies in the LC are associated with 
neuronal dysfunction, death, cognitive/behavioral phenotypes, and the spread of 
pathology 117. Another study showed that accumulation of NFTs in the isodendritic core, 
which includes the LC, may explain AD symptoms including mood disturbances, 
depression, and agitation 118. Furthermore, there was a significant reduction of AD 
cognitive and behavioral symptoms following replenishment of neurotransmitters 
(including NE) associated with the IC network 118. There is also increasing evidence 
implicating NE deficiency in impulsivity in frontotemporal lobar degeneration (FTLD) 
syndromes. Additionally, early and severe FTLD pathology in the LC suggests that 
restoring NE neurotransmission may be a beneficial therapy for impulsivity in this 
neurodegenerative disease 119. Since the LC is the major supply of NE to the CNS, future 
work should evaluate the change in NE within the CNS in relation to the development in 
LC pathology. NE is a critical modulator to a wide variety of structures, as mentioned 
above, and could potentially be altered in CTE due to LC pathology just as it is in other 
neurodegenerative diseases. An alteration in NE or its synapses has the potential to cause 
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significant disruption and symptoms like those seen in CTE 116,117. Unfortunately, we 
were unable to obtain data in regards to NE for this analysis, but should be done in the 
future.  
One possible way to evaluate changes in NE within the CNS is to inject NE 
antagonists into the various structures within rat brains. After decreasing NE transmission 
in areas specific to CTE, clinical symptoms in rats can be evaluated for overlap with 
parallel CTE symptoms. Additionally, another study can examine CNS NE amount in 
humans over the prolonged life course of RHI exposure and compare to CTE 
susceptibility, disease progression, and symptom development. Since NE may potentially 
have a neuroprotective role and modulates numerous CNS functions, we may expect to 
see individuals with decreased CNS NE have unique disease progression, worsened 
disease, or distinctive symptoms 115. 
Additional symptoms related to LC dysfunction should also be analyzed in future 
studies. For example, LC degeneration induced by neuron loss and NFT pathology along 
with dysregulation of the LC-NE system may have a critical role in the development of 
cognitive deficits, sleep disruption, agitation, aggression, anxiety, depression, and 
dementia symptoms seen in AD 121. 
Although our study did not show any correlation between LC p-tau and specific 
CTE symptoms, the role the LC plays in AD and the development of symptoms 
mentioned above does highlight potential linkages that CTE pathology in the LC may 
have with these symptoms, which are often seen in CTE. Uncovering the effect that the 
LC has on various symptoms may enable or improve prevention or treatment. 
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As depression and depressed mood have been strongly associated with CTE and 
the LC has been known to be a contributor to depression, it was important to examine the 
association of LC pathology and symptoms 38. There is also evidence that has shown LC 
has a major role in the origin of clinical depression and possibly suicide and that the LC 
is involved in the behavioral manifestations of depression 122,123. Furthermore, other 
studies have implicated LC pathology as a potential cause of depression and suicide as 
well 22,38. Specifically in MDD, noradrenergic neurotransmission is dysregulated and the 
LC represents a key region in the etiology of the disorder 124. In the current study there 
was a not a significant difference in p-tau density in those diagnosed with MDD 
compared to those who were not diagnosed. This opposed previous notions that LC 
dysfunction may play a role in the development of depression. However, this analysis on 
the association of depression to LC pathology was limited. Depression is heterogeneous, 
multifactorial, and can arise from dysfunctions of several other structures throughout the 
brain, which makes it difficult to specifically identify its relationship with the LC 125.  
As mentioned previously, suicidality has been identified in a large number of 
CTE cases, and a high proportion of confirmed CTE cases have died by suicide 38. 
Suicide is multifactorial and can be caused by depression along with many other 
psychiatric and environmental variables 122,123. For that reason, one should be cautious 
when attributing any specific causes to suicide. There is also ascertainment bias using a 
brain donation cohort for pathological verification of CTE, which makes determining the 
true risk of death by suicide in CTE complicated 22. However, studies have shown altered 
LC, including decreased LC neurons or decreased LC neuronal density, in suicide victims 
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123,126,127. There is evidence showing that individuals who committed suicide had chronic 
activation of the LC 123. This may in part be from a decrease in NE release due to 
increased p-tau pathology in the LC, which can potentially lead to loss of LC neurons and 
decreases CNS NE release. The result of this long‐term activation would be an increased 
depletion of synaptic norepinephrine, further perpetuating the dysregulation and potential 
risk for suicide 123,128. There is evidence showing the likelihood of NE dysfunction and 
depletion contributes to suicide 128. Similar NE disruption may occur in CTE from LC p-
tau build up and LC-NE neuron degeneration, making similar consequences a valid 
possibility. Another factor to consider is that since NE actions have profound effects on 
behaviors commonly disrupted in depression and suicide, and are also seen in CTE, it can 
potentially lead to such outcomes in CTE. There have been no other studies that have 
evaluated the relationship between LC pathology in CTE and suicide. Although it 
difficult to derive a direct link between suicide and CTE pathology in the LC, the 
importance of LC as a regulator of common dysfunctions present in depression and 
suicide necessitates further insight. Future studies should also look at NE alterations in 
the LC due to CTE pathology and relate it to whether disruptions in the LC are typical of 
victims of suicide without CTE. Suicidality (as opposed to death from suicide) should 
also be evaluated in future studies. 
Although we observed increases in tau density that correlated with CTE severity, 
we did not see any difference in specific clinical variables. Future long-term prospective 
studies may look to evaluate individuals using standardized questionnaires and tests 
throughout the course of RHI exposure and through the end of life. Additionally, this 
 48 
study only looked at the density of AT8 within the LC that had visible LC neurons, 
meaning the neuronal density and neuron counts were not examined in this study. 
Neuronal loss potentially has effects on the disease and its symptoms and may show 
differential loss than the accumulation of AT8-immunoreactive tau. Future studies may 
need to evaluate these specific parameters since it was out of the scope of this specific 
study. Lastly, as mentioned above, pathology seems to initially develop at the depths of 
the cortical sulci and the nearby perivascular spaces. However, with the LC at the 
brainstem away from these locations, the mechanism by which p-tau pathology develops 
in the LC remains unknown. Although the LC has been shown to develop pathology early 
in CTE, the pathology may not be significant enough to manifest in symptoms until later 
in the disease course. By this time in the disease course the various symptoms may have 
already developed and the LC pathology rather worsens their presentation rather than 
causes development; however, this is just speculation. Future studies should evaluate the 
severity of symptoms within CTE disease stages. We were unable to do that due to 
examining the symptoms in a binary manner, the difficulty of measuring symptoms 
retrospectively through third parties as discussed, and the lack of available data. The 
mechanism of LC p-tau development may also vary between type of exposure and should 
be evaluated separately. Additional pathologies seen in CTE should be also explored 
including neuroinflammation, Lewy bodies, and TDP-43.  
There are limitations to this study. There is selection bias in an autopsy-based 
study of individuals whose brains are donated by the family so the subjects may not 
represent the population as a whole. Clinical and RHI exposure histories are obtained 
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retrospectively and are subject to bias, which can potentially limit accuracy of the results. 
Various different clinical information may not have been available from every single 
subject. Additional symptoms in more cases will be required to confirm and extend these 
results 59.  
To summarize, LC AT8 density showed a significant positive correlation with 
duration of RHI exposure when controlled for age. There also was a significant increase 
in LC AT8-immunoreactive tau in cases with stage III and IV CTE compared to those 
with no CTE and stage I and II CTE, and AT8 density was predictive of CTE stage when 
controlled for age. There were no significant relationships found between density of LC 
AT8-immunoreactive tau and age of any CTE symptom onset or individual symptom 
(impulsivity, depressed mood, MDD, death by suicide) presence. Additional studies 
should continue to investigate these implications. This study is one of very few focused 
investigations on LC pathology to particular psychiatric dysfunctions, especially those in 
CTE. Discovering the role of LC pathology in CTE will help to understand how the 
disease develops and whether the LC is part of the first changes seen in the disease. 
Furthermore, it may help with generating therapeutic interventions to possibly prevent or 
control the disease progression or its symptoms at the earliest stages. With this 
information in mind, along with the LC’s implications in various other neurodegenerative 
diseases, it is crucial to continue to evaluate CTE pathology in the LC and its effects on 
both the pathological and clinical characteristics of the disease.  
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